RHOA and systemic lupus erythematosus: Conceivably, interruption of this feedback pathway by the pharmacologic targeting RhoA could provide a means to reset type I IFN activation in a manner that would be therapeutically beneficial in lupus but preserve necessary anti-infective responses.